We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.

International Symposium on Amyloidosis

Mayo Clinic

Poster Abstracts - PROGNOSIS ATTR

Fifty years of experience with hereditary transthyretin amyloidosis – first report from the SveATTR registry PC50 (#25)

Performance of prognostic staging systems for Transthyretin Cardiac Amyloidosis in the disease modifying era. PC51 (#45)

Role of age and QRS duration as mortality predictors in a cohort of patients with transthyretin cardiac amyloidosis (ATTR-CA) PC52 (#71)

Autonomic Dysfunction Severity and Cardiovascular Symptoms in ATTR Cardiac Amyloidosis: Insights from the COMPASS-31 Questionnaire PC53 (#86)

Heart failure with preserved, mildly reduced, and reduced left ventricular ejection fraction in patients with transthyretin amyloid cardiomyopathy PC54 (#132)

Clinical utility of the 6-minute walk distance in cardiac transthyretin amyloidosis PC55 (#137)

Prospective, Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin Amyloidosis: Design of the MaesTTRo Study PC56 (#204)

Baseline predictors of major adverse events for transthyretin amyloidosis cardiomyopathy patients treated and untreated with disease-modifying therapy PC57 (#216)

Predictors of Developing Renal Dysfunction Following Diagnosis of Transthyretin Cardiac Amyloidosis PC58 (#236)

Clinical Relevance of NT-Pro BNP at the Time of ATTR Cardiac Amyloidosis Diagnosis PC59 (#237)

Gamma-glutamyltransferase independently predicts all-cause mortality  in transthyretin cardiac amyloidosis PC60 (#247)

The effect of tafamidis treatment on vascular aging in patients with ATTR cardiomyopathy. An observational study PC61 (#310)

The Impact of Frailty and Cardiac Amyloid Burden on 6-minute walk distance in ATTR cardiomyopathy. PC62 (#323)

Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up PC63 (#351)

Transthyretin amyloidosis in Greece:  Outcomes and changing diagnostic patterns PC64 (#353)

A Natural History Study of Transthyretin (ATTR) Amyloidosis: Trends in Overall Survival at a U.S. Referral Center PC65 (#373)

Left Ventricular Obstruction in Transthyretin amyloid cardiomyopathy PC66 (#381)

Impact of upgrading to cardiac resynchronization therapy or left bundle branch pacing in patients with ATTR cardiomyopathy PC67 (#389)

Natriuretic peptides, atrial fibrillation, and survival in patients with transthyretin cardiomyopathy receiving tafamidis treatment. PC68 (#395)

Incidence of pacemaker implantation and prognostic value on all-cause mortality in wild-type transthyretin amyloidosis PC69 (#398)

Incidence and prognostic implications of atrial fibrillation in wild-type transthyretin amyloidosis cardiomyopathy PC70 (#400)

Evolution of Transthyretin Amyloid Cardiomyopathy Characteristics Over a 20 Year Period: A Multicenter Study of 1,168 Patients PC71 (#428)

A Multicenter Study of Real-World Outcomes of Tafamidis in Transthyretin Amyloid Cardiomyopathy PC72 (#429)

Predictors of early mortality in patients with wild-type transthyretin cardiac amyloidosis PC73 (#450)

Reduction in All-Cause Mortality in ATTR-CM Over a 20 year Period PC74 (#453)

Transthyretin Amyloidosis: Does more than one pathogenic variant confer higher severity? PC75 (#478)

Can patisiran stop the progression of cardiac amyloidosis in patients with ATTRE109Q amyloidosis? Description of a monocentric experience. PC76 (#487)

Role of Blood Biomarkers in Hereditary transthyretin amyloidosis: A Real-World Experience from a Single Center. PC77 (#493)

Interventricular septum diameter as an echocardiographic predictor of thromboembolic events (TEEs) in patients with cardiac amyloidosis (CA) without atrial fibrillation diagnosis PC78 (#504)

Predictors of atrial fibrillation in Brazilian patients with transthyretin amyloidosis cardiomyopathy: Insights from the REACT registry. PC79 (#526)

Prevalence of frailty in a contemporary population of ATTR cardiac amyloidosis PC80 (#562)

Survival in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy Over a 20-Year Period PC81 (#566)

Lack of an association between baseline or follow-up transthyretin levels and all-cause mortality in ATTR cardiomyopathy patients on tafamidis PC82 (#569)